Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Employment/Membership › Details

Swedish Orphan Biovitrum–Barnes D: management, 202101– Head of North America before UCB Inc + Amgen + Prime Therapeutics + Aetna + Medco Health

 

Period Period 2021-01-01
Region Region North America
Organisations Organisation Swedish Orphan Biovitrum (Sobi) (Group)
  Organisation 2 UCB Inc.
  Group UCB (Group)
Products Product pharmaceutical
  Product 2 DRUGS, ORPHAN
Person Person Barnes, Duane (Swedish Orphan Biovitrum 202101– Head of North America before UCB Inc + Amgen + Prime Therapeutics)
     

Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase".

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has appointed Duane Barnes as the new Head of Sobi in North America.

"Sobi in North America has gone through significant change over the past few years and has exciting launches both underway and coming up in the years ahead," says Guido Oelkers, CEO and President of Sobi. "This is why it is such a pleasure to welcome Duane to Sobi. His experience and background will be invaluable as we continue to build our presence in the US and fulfil our commitment to further expand access to patients."

Duane was most recently President of UCB Inc and Head of US Operations with responsibility for key functions. Prior to UCB he has held executive roles at Amgen, Prime Therapeutics, Aetna, Medco Health Solutions, Merck-Medco and Quest Diagnostics.

He has a strong background in the US healthcare sector and lengthy experience working cross-functionally to find new ways to deliver value to patients living with severe diseases. Duane has a MSc and MBA from the Indiana University and sits on the boards of the Biotechnology Innovation Organization (BIO) and the Healthcare Leadership Council (HLC).

Duane will join Sobi in January 2021 and be part of the Executive Committee.


About SobiTM

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.


Contact

Paula Treutiger, Head of Communication & Investor Relations
+46 733 666 599
paula.treutiger@sobi.com

Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com

   
Record changed: 2021-02-15

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Swedish Orphan Biovitrum (Sobi) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top